Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
FBN1-related Marfan syndrome (Marfan syndrome), a systemic disorder of connective tissue, is part of a broad phenotypic continuum associated with heterozygous FBN1 pathogenic variants that ranges from mild (features of Marfan syndrome in one or a few systems) to severe (rapidly progressive multiorgan disease in neonates). Cardinal manifestations of Marfan syndrome involving the ocular, skeletal, and cardiovascular systems have a high degree of clinical variability. Table 3. FBN1-Related Marfan Syndrome: Frequency of Cardinal Manifestations in Adults by System
Consensus clinical diagnostic criteria for FBN1-related Marfan syndrome (Marfan syndrome) have been published . Suggestive Findings Marfan syndrome should be suspected in individuals with the following clinical findings and family history. Clinical findings • Aortic root enlargement (z score ≥2.0). Note: Aortic size must be standardized to age and body size for accurate interpretation. A z score ≥2.0 indicates a value at or above the 95th percentile, while a z score ≥3.0 indicates a value at or above the 99th percentile. References and calculators for this determination are available at the Marfan Foundation website. • Ectopia lentis; most reliably diagnosed by slit-lamp examination after maximal pupillary dilation • A systemic score ≥7 Table 1. Calculation of the Systemic Score
No approved treatments are currently available for overlapping connective tissue disease. The disease remains an area of unmet medical need.
No comprehensive or widely adopted clinical practice guidelines for FBN1-related Marfan syndrome (Marfan syndrome) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with FBN1-related Marfan syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 7. Recommended Evaluations Following Initial Diagnosis in Individuals with FBN1-Related Marfan Syndrome
Table 9. Recommended Surveillance for Individuals with FNB1-Related Marfan Syndrome
System/Concern |
|---|
No clinical trials have been registered for overlapping connective tissue disease.
7 publications have been identified in PubMed for overlapping connective tissue disease. Research spans Case Report / Case Series (57%), Review / Meta-Analysis (29%), and Basic Science / Preclinical (14%).
Tan YR (2026). [PMID: 41635383](https://pubmed.ncbi.nlm.nih.gov/41635383/). *Cureus*. [Case Report / Case Series]
Greaves B (2025). [PMID: 40918607](https://pubmed.ncbi.nlm.nih.gov/40918607/). *Clinical medicine insights. Arthritis and musculoskeletal disorders*. [Case Report / Case Series]
Maraj D (2025). [PMID: 41058845](https://pubmed.ncbi.nlm.nih.gov/41058845/). *Cureus*. [Case Report / Case Series]
Bahir AW (2025). [PMID: 41541920](https://pubmed.ncbi.nlm.nih.gov/41541920/). *Cureus*. [Case Report / Case Series]
Dreher L (2025). [PMID: 40981152](https://pubmed.ncbi.nlm.nih.gov/40981152/). *Medical sciences (Basel, Switzerland)*. [Review / Meta-Analysis]
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
System | Feature1 | % of Personsw/Feature | Comment |
|---|---|---|---|
Ocular | Myopia | 50% | — |
Ectopia lentis | ~60% | — | — |
Retinal detachment | 25% | — | — |
Glaucoma | ~30% | — | — |
Early cataracts | 25% | — | — |
Skeletal2 | Joint laxity | 50% | — |
Disproportionately long extremities for size of trunk (dolichostenomelia) | 50% | Typically due to bone overgrowth | — |
Pectus anomaly3 | ~50% | Excavatum carinatum have both been described. | — |
Scoliosis | ~60% | Ranges from mild to severe progressive | — |
Cardiovascular4 | Dilatation of aorta at level of sinuses of Valsalva | 80% | — |
Aortic tear rupture | 25% | Risk is greatly w/proper medical surgical mgmt. | — |
Mitral valve prolapse | 50% | W/or w/o regurgitation | — |
Tricuspid valve prolapse | 25% | Enriched in those w/infantile presentations of severe MFS | — |
Enlargement of the proximal pulmonary artery | ~50% | Dissection or rupture is exceedingly rare in this population. MFS = FBN1-related Marfan syndrome Many of the features of Marfan syndrome are not recognized in infancy/childhood or develop later in life. However, in severe cases, some of these features may be present in infancy and/or childhood. 2. | — |
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
Feature | Value | Enter Value if Feature Is Present |
|---|---|---|
Wrist AND thumb sign | 3 | — |
Wrist OR thumb sign | 1 | — |
Pectus carinatum deformity | 2 | — |
Pectus excavatum or chest asymmetry | 1 | — |
Hindfoot deformity | 2 | — |
Plain flat foot (pes planus) | 1 | — |
Pneumothorax | 2 | — |
Dural ectasia | 2 | — |
Protrusio acetabulae | 2 | — |
Reduced upper segment to lower segment AND increased arm span to height ratios | 1 | — |
Scoliosis or thoracolumbar kyphosis | 1 | — |
Reduced elbow extension | 1 | — |
3 of 5 facial features | 1 | — |
Skin striae | 1 | — |
Myopia | 1 | — |
Mitral valve prolapse | 1 | Total A systemic score calculator and a complete description of each component evaluation can be found at the Marfan Foundation website. Family history is consistent with autosomal dominant inheritance (e.g., affected males and females in multiple generations). |
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
Loeys-Dietz syndrome (LDS) is an autosomal dominant condition that includes many features of Marfan syndrome (long face, downslanted palpebral fissures, highly arched palate, malar hypoplasia, micrognathia, retrognathia, pectus deformity, scoliosis, arachnodactyly, joint laxity, dural ectasia, and aortic root aneurysm with dissection). Some features of Marfan syndrome are either less common or prominent (dolichostenomelia) or absent (ectopia lentis). Unique features can include widely spaced eyes, broad or bifid uvula, cleft palate, hydrocephalus (rare), Chiari I malformation, blue sclerae, exotropia, craniosynostosis, cervical spine instability, talipes equinovarus, soft and velvety skin, translucent skin, easy bruising, milia, generalized arterial tortuosity, and frequent aneurysms and dissection throughout the arterial tree. Individuals with LDS are at risk for cervical spine malformation and/or instability, food and environmental allergies, asthma, eczema, eosinophilic esophagitis, and inflammatory bowel disease (rare). Aortic aneurysms in LDS behave very differently from those in Marfan syndrome, with frequent dissection and rupture at small dimensions and in early childhood. LDS results from a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2. Shprintzen-Goldberg syndrome (SGS). The phenotype of SGS is distinctive but shows significant overlap with LDS and Marfan syndrome. Major distinctions include the unique and highly penetrant developmental delay in SGS, with less frequent and milder cardiovascular manifestations than in either Marfan syndrome or LDS. Table 5. Comparison of Clinical Features in Marfan Syndrome, Loeys-Dietz Syndrome, and Shprintzen-Goldberg Syndrome
Clinical Feature | MarfanSyndrome | Loeys-Dietz Syndrome | Shprintzen-GoldbergSyndrome |
|---|---|---|---|
TGFB3 | SMAD2 | — | — |
SKI Developmental delay | ++ | — | — |
Ectopia lentis | +++ | — | — |
Cleft palate / bifid uvula | ++ | + | + |
Widely spaced eyes | ++ | + | + |
Craniosynostosis | ++ | + | +++ |
Tall stature | +++ | + | + |
Arachnodactyly | +++ | ++ | + |
Pectus deformity | ++ | ++ | ++ |
Clubfoot | ++ | + | ++ |
Osteoarthritis | + | + | +++ |
Aortic root aneurysm | +++ | ++ | ++ |
Arterial aneurysm | ++ | + | + |
Arterial tortuosity | ++ | ++ | + |
Early dissection | + | +++ | ++ |
Bicuspid aortic valve | ++ | + | + |
Mitral valve insufficiency | ++ | + | + |
Striae | ++ | + | + |
Dural ectasia | + | + | + |
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of length/height | To assess for tall stature growth1 |
Eyes | Ophthalmologic eval, ideally by ophthalmologist w/expertise in MFS | To incl:; Slit lamp exam through maximally dilated pupil for evidence of lens subluxation; Refraction, esp in young children at risk for amblyopia; Assessment for glaucoma cataract |
Musculoskeletal | Clinical assessment for skeletal manifestations that may require immediate attn of an orthopedist (e.g., severe scoliosis) | — |
Dental | Assessment by dentist | For dental crowding palatal issues |
Cardiovascular | Echocardiography2 | Esp aortic root measurements, which must be based on consideration of normal values for age body size; click here for a calculator. |
Neurologic | Consider spinal MRI to assess for dural ectasia. | In those w/low back pain, proximal leg pain, weakness numbness above knee genital/rectal pain |
Skin | Clinical assessment for hernias | — |
Respiratory | Consider chest radiograph to assess for pneumothorax. | In those w/pain in chest, dyspnea, chest tightness, /or cyanosis Genetic |
counseling | By genetics professionals3 | To inform affected persons their families re nature, MOI, implications of MFS to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with FBN1-Related Marfan Syndrome Manifestation/Concern | Treatment | Considerations/Other |
Tall stature | Use of hormone supplementation to limit adult height is rarely requested or considered.1 | This treatment should only be considered when an extreme height is anticipated. |
Refractive errors | Standard treatment per ophthalmologist | Spectacle correction is often adequate.; Prompt aggressive assessment correction of refractive error is mandatory in young children at risk for amblyopia. |
Lens dislocation | May require surgical aphakia (removal of lens) if lens is freely mobile or margin of lens obstructs vision | An intraocular lens can be implanted after puberty (i.e., once growth is complete).; While intraocular lens implants are currently considered quite safe when performed in specialized centers, major complications incl retinal detachment can occur. Glaucoma/ Cataracts/ |
Retinal detachment | Standard treatment per ophthalmologist | — |
Severe /or progressive scoliosis | Bracing or surgical stabilization of spine may be required. | — |
Pectus deformity | Standard treatment per orthopedist or general surgeon | In very rare circumstances, surgical intervention is indicated for medical (rather than cosmetic) reasons. |
Protusio acetabulae | Functional deficits or pain may respond to PT, analgesics, or anti-inflammatory medications. | Surgical intervention is rarely indicated. Pes planus |
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
The following should be avoided:
Contact sports, competitive sports, and isometric exercise. Note: Individuals can and should remain active with aerobic activities performed in moderation.
Activities that cause joint injury or pain
Agents that stimulate the cardiovascular system including routine use of decongestants. Caffeine can aggravate a tendency for arrhythmia.
Agents that cause vasoconstriction, including triptans
LASIK eye surgery to correct refractive errors
For individuals at risk for recurrent pneumothorax, breathing against resistance (e.g., playing a brass instrument) or positive pressure ventilation (e.g., SCUBA diving)
Fluoroquinolone antibiotics due to the considerable evidence suggesting exacerbation of predisposition for aneurysm and dissection
Avoidance of classes of antihypertensive agents (e.g., calcium channel blockers, ACE inhibitors) where there is an absence of direct evidence for their efficacy or safety in individuals with Marfan syndrome
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
View trials for overlapping connective tissue disease
Evaluation
Frequency |
|---|
Constitutional | Measurement of length/height/weight1 | At each visit |
Eyes | Ophthalmologic exam incl specific assessment for glaucoma cataracts | At least annually, or as clinically indicated |
Musculoskeletal | Clinical assessment for chest wall deformities scoliosis2 | At each visit until skeletal maturity; severe scoliosis may require ongoing surveillance in adulthood. |
Dental | Dental eval (incl orthodontia, as indicated) | At least annually after eruption of teeth |
Cardiovascular3 | Echocardiography | Annually when aortic dimension is relatively small rate of aortic dilatation is relatively slow; More often than annually when aortic root diameter ~4.5 cm in adults, rate of aortic dilatation ~0. |
Source: GeneReviews — "FBN1-Related Marfan Syndrome"
Huguet Herrero J (2025). [PMID: 40657314](https://pubmed.ncbi.nlm.nih.gov/40657314/). *medRxiv : the preprint server for health sciences*. [Review / Meta-Analysis]
Han D (2024). [PMID: 38958168](https://pubmed.ncbi.nlm.nih.gov/38958168/). *Molecular genetics & genomic medicine*. [Basic Science / Preclinical]
AI-curated news mentioning overlapping connective tissue disease
Updated Sep 9, 2026
A systematic literature review highlights the importance of early detection and treatment initiation in improving long-term health outcomes for patients with connective tissue disease-associated pulmonary arterial hypertension. Expert consensus emphasizes the need for enhanced screening protocols.
The large dose of brepocitinib, a JAK1/TYK2 inhibitor, showed benefits on a composite score and secondary end points. The FDA has set a PDUFA date for the drug in the third quarter of 2026, according to its developer. Close to 10% (9.95) of the patients randomly assigned to the 30-mg dose of brepocitinib experienced a serious infection during the yearlong trial, compared with 2.5% of the patients assigned to the 15-mg dose and 1.3% in the placebo group. Vleugels noted that brepocitinib was “layered on” other treatments. “For those who are experts in dermatomyositis, this would be something we would expect. The more therapies you lay on, you have to be mindful of infections,” she said. The primary end point was a composite of six measures of myositis activity called the Total Improvement Score. Vleugels said that score has been used in other studies of treatments for dermatomyositis and that it encompasses both the muscle and skin aspects of the disease. The trial design called for a treatment period of 52 weeks. “If you had asked me when I started practicing almost 20 years ago if we would ever have a pivotal Phase 3, global, randomized controlled trial in dermatomyositis, I don’t know if I would have believed it,” co-lead author · Ruth Ann Vleugels, M.D., M.P.H., MBA, a professor of dermatology at Harvard Medical School and director of Connective Tissue Disease Clinics at Harvard-affiliated Brigham and Women’s Hospital, said in an interview with Managed Healthcare Executive. Brepocitinib, the agent assessed in the trial, is an oral drug that inhibits Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), a duality that explains its efficacy because it stifles multiple cytokines implicated in the pathogenesis of dermatomyositis in addition to interferon 1 and 2, Vleugels said. The FDA has put brepocitinib in a category that is supposed to mean a speedier review process. Priovant Therapeutics, the Durham, North Carolina, company that developed brepocitinib, says its product has a Prescription Drug User Fee Act (PDUFA) date — the date on which the FDA is supposed to make a decision on whether to approve a drug — in the third quarter of this year.
A recent study published in PubMed highlights the extended follow-up of CD19 CAR T-cell therapy in patients with connective tissue disease-associated pulmonary arterial hypertension. This research contributes to understanding the potential of CAR T-cell therapy in rare diseases.
analysis of clinical manifestations and therapeutic outcomes in pediatric connective tissue disease associated interstitial lung disease